Table 2. IC50 values for erlotinib, afatinib and gemcitabine in pancreatic cancer cell lines assessed by the SRB colorimetric assay and combination index (CI) values of gemcitabine plus afatinib or erlotinib in pancreatic cancer cell lines.
IC50 value
|
|||||
---|---|---|---|---|---|
Cell line | Erlotinib | Afatinib | Gemcitabine | Afatinib+gemcitabine combination index (effect) | Erlotinib+gemcitabine combination index (effect) |
BxPC-3 | 1.26 μM | 11 nM | 7.4 nM | 0.31 (Synergism) | 0.46 (Synergism) |
AsPc-1 | 5.8 μM | 367 nM | 87.3 nM | 0.62 (Synergism) | 0.69 (Synergism) |
FA6 | >20 μM | 1.37 μM | 5.23 nM | 0.85 (Slight synergism) | N/A |
PANC-1 | >20 μM | 966 nM | 21.4 nM | 0.73 (Moderate synergism) | N/A |
Capan-1 | >20 μM | 781 nM | 104.9 nM | 0.88 (Slight synergism) | 0.66 (Synergism) |
MiaPaCa-2 | >20 μM | 709 nM | 6.4 nM | 1.25 (Moderate antagonism) | 1.30 (Moderate antagonism) |
PT-45 | >20 μM | 1.02 μM | 14.3 nM | 1.40 (Moderate antagonism) | 0.54 (Synergism) |
Abbreviations: N/A=not available; IC50=50% inhibitory concentration; SRB=Sulforhodamine B.
Interpretation of the results was based on the proposed descriptions for presenting the degrees of antagonism or synergism by Calcusyn software